EGFR and neoplasm: Cetuximab (Erbitux, Merck-Serono, Darmstadt, Germany) is a chimeric monoclonal antibody (IgG1) that binds to the ectodomain of the human EGFR and competitively inhibits ligand binding to suppress tumor proliferation.